Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations

Tytuł :
Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
Autorzy :
Gourley, Charlie
Hollis, Robert L.
Meynert, Alison M.
Churchman, Michael
Rye, Tzyvia
Mackean, Melanie
Nussey, Fiona
Arends, Mark J.
Sims, Andrew H.
Semple, Colin A.
Herrington, C. Simon
Pokaż więcej
Temat :
Retrospective Studies
Research Article
skin and connective tissue diseases
Doxorubicin/analogs & derivatives
Cystadenocarcinoma, Serous/drug therapy
BRCA2 Protein/genetics
endocrine system diseases
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Neoplasm Grading
BRCA1 Protein/genetics
Polymorphism, Single Nucleotide
Survival Rate
BRCA1
Female
BRCA2
Polyethylene Glycols/therapeutic use
Ovarian cancer
Ovarian Neoplasms/drug therapy
Aged
Middle Aged
Biomarkers, Tumor/genetics
Mutation
Follow-Up Studies
PLDH
RC254-282
Genetic Predisposition to Disease
Adult
Aged, 80 and over
Antibiotics, Antineoplastic/therapeutic use
Humans
Źródło :
Hollis, R L, Meynert, A, Churchman, M, Rye, T, Mackean, M, Nussey, F, Arends, M, Sims, A, Semple, C, Herrington, C & Gourley, C 2018, ' Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations ', BMC Cancer, vol. 18, no. 1, pp. 16 . https://doi.org/10.1186/s12885-017-3981-2
BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)
Wydawca :
BMC, 2018.
Rok publikacji :
2018
Kolekcja :
DOAJ-Articles_enriched
DOAJ-Articles
Oryginalny identyfikator :
pmc: PMC5753521
pmid: 29298688
Opis pliku :
application/pdf
Język :
English
ISSN :
1471-2407
DOI :
10.1186/s12885-017-3981-2
Background Approximately 10–15% of ovarian carcinomas (OC) are attributed to inherited susceptibility, the majority of which are due to mutations in BRCA1 or BRCA2 (BRCA1/2). These patients display superior clinical outcome, including enhanced sensitivity to platinum-based chemotherapy. Here, we seek to investigate whether BRCA1/2 status influences the response rate to single-agent pegylated liposomal doxorubicin (PLD) in high grade serous (HGS) OC. Methods One hundred and forty-eight patients treated with single-agent PLD were identified retrospectively from the Edinburgh Ovarian Cancer Database. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) archival tumour material and sequenced using the Ion Ampliseq BRCA1 and BRCA2 panel. A minimum variant allele frequency threshold was applied to correct for sequencing artefacts associated with formalin fixation. Results A superior response rate to PLD was observed in patients with HGS OC who harboured variants likely to affect BRCA1 or BRCA2 function compared to the BRCA1/2 wild-type population (36%, 9 of 25 patients versus 12.1%, 7 of 58 patients; p = 0.016). An enhanced response rate was also seen in patients harbouring only the BRCA1 SNP rs1799950, predicted to be detrimental to BRCA1 function (50%, 3 of 6 patients versus 12.1%, 7 of 58 patients; p = 0.044). Conclusions These data demonstrate that HGS OC patients with BRCA1/2 variants predicted damaging to protein function experience superior sensitivity to PLD, consistent with impaired DNA repair. Further characterisation of rs1799950 is now warranted in relation to chemosensitivity and susceptibility to developing ovarian carcinoma. Electronic supplementary material The online version of this article (10.1186/s12885-017-3981-2) contains supplementary material, which is available to authorized users.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies